Roxane Agrees To Hold Off On Generic Asacol

Law360, New York (March 12, 2010, 1:52 PM EST) -- Roxane Laboratories Inc. has agreed to delay its launch of a generic version of inflammatory bowel drug Asacol until as late as November as part of a discovery agreement in a patent infringement suit brought by Procter & Gamble Pharmaceuticals Inc. and Medeva Pharma Suisse AG.

Roxane filed a stipulation Thursday in the U.S. District Court for the District of New Jersey agreeing not to sell the drug before Nov. 1 or “the date of favorable judgment, whichever is earlier,” even though the U.S. Food and...
To view the full article, register now.